|Last Price$75.88||Day Change (%)0.41%|
|Open Price$77.25||Day Change ($)0.31|
|Day Range75.25–77.25||52-Week Range49.96–110.75|
As of Mon 9/26/2016 2:16:00 PM | USD
Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1
Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight - Research and Markets
This Gold-rated fund is not a safe choice, but it's a strong one for the right kind of investor.
Use this screen to find high-growth businesses that have big ideas to keep competitors at bay.